Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Core Insights - Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion in cash, enhancing its oncology pipeline [1] Company Summary - The acquisition of Halda Therapeutics is a strategic move for Johnson & Johnson to strengthen its position in the oncology sector [1] - The deal reflects Johnson & Johnson's commitment to expanding its healthcare offerings through targeted investments in biotechnology [1]